Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Adial Pharmaceuticals (ADIL) Non Operating Investment Income (2022 - 2023)

Adial Pharmaceuticals' Non Operating Investment Income history spans 2 years, with the latest figure at -$14000.0 for Q1 2023.

  • For Q1 2023, Non Operating Investment Income fell 109.59% year-over-year to -$14000.0; the TTM value through Mar 2023 reached $362000.0, changed N/A, while the annual FY2022 figure was $522000.0, 285.29% up from the prior year.
  • Non Operating Investment Income for Q1 2023 was -$14000.0 at Adial Pharmaceuticals, down from $325000.0 in the prior quarter.
  • Across five years, Non Operating Investment Income topped out at $325000.0 in Q4 2022 and bottomed at -$24000.0 in Q2 2022.